Sarilumab, an anti–IL-6R human monoclonal antibody, also seems to reduce HbA1c values in diabetic and nondiabetic patients with RA compared with placebo, which is supporting favorable effects of blocking IL-6R signaling on glucose metabolism [48]. The gene discussed is IL6R; the disease is rheumatoid arthritis.